Bellicum Pharmaceuticals, Inc.
METHODS TO AUGMENT OR ALTER SIGNAL TRANSDUCTION
Last updated:
Abstract:
The technology relates generally to the field of immunology and relates in part to compositions and methods for activating cells, including, for example T cells that express chimeric antigen receptors or recombinant TCRs, and reducing cytotoxicity, using chimeric polypeptides including MyD88 and signaling domains of receptor mediators of costimulation.
Status:
Application
Type:
Utility
Filling date:
8 May 2018
Issue date:
20 May 2021